Physician profile
Alejandro Delvalle
NPI 1720080609
$11,612.79
in general payments reported to CMS, 2019-2025
42 companies · $1,372 in 2025
The $1,372 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,460 · 2020: $954 · 2021: $1,443 · 2022: $1,166 · 2023: $1,540 · 2024: $1,678 · 2025: $1,372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,590.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $1,743.20 | 2019 | |
| Abbvie INC. | $1,549.49 | 2021-2025 | Avycaz |
| Novo Nordisk INC | $1,385.79 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $1,075.86 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $830.42 | 2019-2024 | Xarelto |
| Allergan, INC. | $756.67 | 2019-2020 | |
| Amarin Pharma, INC. | $549.95 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $435.14 | 2019-2025 | Eliquis |
| Lilly USA, LLC | $413.09 | 2020-2025 | Mounjaro, Zepbound |
| Viiv Healthcare Company | $357.54 | 2024-2025 | Apretude |
| Gilead Sciences, INC. | $322.20 | 2024 | Veklury |
| Abbott Laboratories | $192.24 | 2023-2024 | Gallant, Aveir |
| Idorsia Pharmaceuticals US INC | $169.16 | 2023-2024 | Quviviq |
| Saluda Medical Americas, INC. | $153.11 | 2024 | Evoke |
| Actelion Pharmaceuticals US, INC. | $147.68 | 2025 | Opsumit, Uptravi |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Delvalle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.